Conditions: PTCH1 or SMO Activated Solid and Hematologic Tumors
Keywords: Solid tumor malignancy, hematologic malignancy, mutation, translocations, signature, PTCH1, SMO, LDE225, endometrial cancer, colon cancer, bladder, NSCLC
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study

Detailed description:

Arms:
arm 1: LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule.

Interventions: intervention 1: LDE225
Intervention descriptions: intervention 1: LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule

Protocol document: